OHCM
SUPN icon

Orchard Hill Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Orchard Hill Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-116,100
Closed -$851K – 29
2013
Q3 		$851K Buy
+116,100
New +$780K 0.04% 23

Other funds holding SUPN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MOACM
Mutual of America Capital Management New York $8.8B AUM 29.06% 1-Year Est. Return

Orchard Hill Capital Management's SUPN Position: Q4 2014 in Review

Orchard Hill Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2014, closing a stake of 1,144,514 shares — an estimated $9.95M sold.

Orchard Hill Capital Management first reported a position in SUPN in Q3 2013 and held it in 5 quarters. The position peaked at $13.9M in Q2 2014. 107 funds tracked by Wall St. Rank hold SUPN as of Q4 2014.

  • Orchard Hill Capital Management reported no remaining Supernus Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Orchard Hill Capital Management sold 1,144,514 Supernus Pharmaceuticals shares in Q4 2014, an estimated $9.95M.
  • Orchard Hill Capital Management first reported a position in Supernus Pharmaceuticals in Q3 2013 and held it in 5 quarters.
  • Orchard Hill Capital Management's Supernus Pharmaceuticals position peaked at $13.9M in Q2 2014.
  • 107 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2014.

Based on Orchard Hill Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.